Glaukos (GKOS) & The Competition Head-To-Head Comparison
Glaukos (NYSE: GKOS) is one of 19 publicly-traded companies in the “Medical Devices & Implants” industry, but how does it contrast to its peers? We will compare Glaukos to similar businesses based on the strength of its institutional ownership, valuation, analyst recommendations, risk, earnings, dividends and profitability.
Earnings and Valuation
This table compares Glaukos and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Glaukos||$114.40 million||$4.52 million||-638.09|
|Glaukos Competitors||$1.67 billion||$207.58 million||87.48|
This table compares Glaukos and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Glaukos has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500. Comparatively, Glaukos’ peers have a beta of 0.47, meaning that their average stock price is 53% less volatile than the S&P 500.
Insider & Institutional Ownership
99.2% of Glaukos shares are held by institutional investors. Comparatively, 54.8% of shares of all “Medical Devices & Implants” companies are held by institutional investors. 16.4% of Glaukos shares are held by company insiders. Comparatively, 11.9% of shares of all “Medical Devices & Implants” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This is a breakdown of current recommendations for Glaukos and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Glaukos currently has a consensus target price of $47.50, suggesting a potential upside of 86.06%. As a group, “Medical Devices & Implants” companies have a potential upside of 35.25%. Given Glaukos’ stronger consensus rating and higher probable upside, equities analysts clearly believe Glaukos is more favorable than its peers.
Glaukos beats its peers on 10 of the 13 factors compared.
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream. It is developing three additional pipeline products: the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is a drug delivery system that is designed to be implanted in the eye to continuously deliver therapeutic levels of medication for extended periods of time to lower intraocular pressure in glaucoma patients.
Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.